← Back to Search

Acupuncture for Chronic Pain (PEACE Trial)

N/A
Waitlist Available
Led By Jun Mao, MD, MSCE
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Inflammatory arthritis that require disease modifying drugs (e.g. rheumatoid arthritis)
Phantom limb pain
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is studying two types of acupuncture compared to usual care on treating chronic pain.

Who is the study for?
Adults over 18 with chronic pain for at least 3 months, experiencing significant pain levels, and have musculoskeletal issues like fibromyalgia. Cancer patients can join if they've finished active treatment a month prior but not if they have metastatic disease. Excludes those with inflammatory arthritis on specific drugs, non-musculoskeletal sole pain conditions, phantom limb pain, electronic medical implants or pending disability claims.
What is being tested?
The PEACE trial is testing two acupuncture techniques against standard care in managing chronic pain. Participants are divided into three groups: one receives Electro-Acupuncture (EA), another Battle Field Acupuncture (BFA), and the third group gets usual care before later receiving acupuncture.
What are the potential side effects?
Acupuncture may cause minor side effects such as soreness or bruising at needle sites, bleeding, dizziness during treatment. Serious side effects are rare but can include infections or injury to underlying tissues.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I take medication for inflammatory arthritis like rheumatoid arthritis.
Select...
I experience pain in a limb that has been amputated.
Select...
I have a history of cancer that has spread, and it is not currently in remission.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Active Control
Group I: Electro-Acupuncture (EA) ProcedureActive Control1 Intervention
Participants will receive 10 treatment of EA acupuncture over the course of 10 weeks (with a maximum of 2 treatments per week).
Group II: Battle Field Acupuncture (BFA) ProcedureActive Control1 Intervention
Participants will receive 10 treatment of BFA acupuncture over the course of 10 weeks (with a maximum of 2 treatments per week).
Group III: Wait List Control (WLC) Usual Care ProcedureActive Control3 Interventions
Subjects in the WLC group continue to receive their standard medical care and pain management as prescribed by their physicians or other health care providers, including analgesic medications. After the 12 week follow up period, patients in the WLC will receive up to ten treatments of either EA or BFA based on their personal preference.

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,965 Previous Clinical Trials
596,623 Total Patients Enrolled
1 Trials studying Pain Management
231 Patients Enrolled for Pain Management
Jun Mao, MD, MSCEPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
9 Previous Clinical Trials
1,710 Total Patients Enrolled

Media Library

Battle Field Acupuncture Clinical Trial Eligibility Overview. Trial Name: NCT02979574 — N/A
Pain Management Research Study Groups: Electro-Acupuncture (EA) Procedure, Battle Field Acupuncture (BFA) Procedure, Wait List Control (WLC) Usual Care Procedure
Pain Management Clinical Trial 2023: Battle Field Acupuncture Highlights & Side Effects. Trial Name: NCT02979574 — N/A
Battle Field Acupuncture 2023 Treatment Timeline for Medical Study. Trial Name: NCT02979574 — N/A
~40 spots leftby Nov 2025